TransCelerate BioPharma, a nonprofit founded by the world's biggest drugmakers to make R&D more efficient, is encouraging developers to adopt risk-based monitoring for clinical trials, disclosing its thinking in two research papers. Published in the Drug Information Association's Therapeutic Innovation & Regulatory Science journal, TransCelerate's papers dig into how companies can best implement adaptive trial designs and which technologies can speed their way. News